Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects
Top Cited Papers
- 1 September 2004
- journal article
- research article
- Published by Elsevier BV in Chest
- Vol. 126 (3), 234S-264S
- https://doi.org/10.1378/chest.126.3_suppl.234s
Abstract
No abstract availableKeywords
This publication has 94 references indexed in Scilit:
- Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventionsAmerican Heart Journal, 2003
- Administration of abciximab to patients receiving tirofiban or eptifibatide: effect on platelet functionJournal of the American College of Cardiology, 2001
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000
- Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudyThe American Journal of Cardiology, 2000
- Abciximab-associated profound thrombocytopenia: Therapy with immunoglobulin and platelet transfusionThe American Journal of Cardiology, 1996
- Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary interventionThe American Journal of Cardiology, 1995
- Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectorisThe Lancet, 1992
- Isolation and covalent structure of the aspirin-modified, active-site region of prostaglandin synthetaseBiochemistry, 1983
- Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: Danger of aspirin compared with dipyridamoleThe American Journal of Cardiology, 1983
- Prevention of arterial thromboembolism with acetylsalicylic acidAmerican Heart Journal, 1977